Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2026 Earnings Call Transcript
Lexicon (LXRX) Q3 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q3 2026 Beat Rests on Novo Milestone as SONATA-HCM and ZYNQUISTA Catalysts Loom
Lexicon: Q3 Earnings Snapshot
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript
Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.